Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplastons A10 and AS2-1 in Stage IV Lung Cancer
NCT00003491Phase 2Terminated
- Sponsor
- Burzynski Research Institute
- Start
- Mar 1996
- Primary completion
- Jul 1998
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antineoplaston A10 and antineoplaston AS2-1 in lung cancer, sponsored by Burzynski Research Institute. Primary endpoints: Objective Response Rate up to 12 months and Safety and Tolerance up to 12 months. Started Mar 1996; status: terminated.
02
Drugs
antineoplaston A10antineoplaston AS2-1
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT00003491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003491.